Maik Schuler

Pfizer (United States)

Papers

1

Total Citations

74

H-Index

1

About

Dr. Maik Schuler is a leading toxicologist whose research focuses on advancing genotoxicity testing through high-content, mechanism-based approaches. His most influential work centers on developing and validating multiplexed in vitro assays that integrate multiple biomarkers of DNA damage and cellular stress into a single, rapid flow cytometric analysis. Schuler’s landmark 2017 study, cited 74 times, describes a groundbreaking interlaboratory evaluation of a multiplexed assay that simultaneously measures p53 activation, γH2AX foci (a marker of DNA double-strand breaks), and phospho-histone H3 (a mitotic marker) in detergent-liberated nuclei. This work demonstrated exceptional reproducibility across laboratories, establishing a new standard for high-information-content genotoxicity screening that reduces false positives while providing mechanistic insight. By incorporating a known number of reference beads for absolute quantification, Schuler’s method enables precise, objective data analysis. His contributions have significantly improved the predictive power and throughput of in vitro genotoxicity assessments, directly impacting regulatory safety evaluations and pharmaceutical development. Schuler’s research bridges fundamental DNA damage biology with practical, high-throughput toxicology, making him a pivotal figure in modern genetic toxicology.

Research Focus

Key Achievements

1
H-Index
1
Papers
74
Total Citations
74
Avg Citations/Paper
🏆 Most Cited Paper
Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay
74 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago